secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioAtla, Inc. (BCAB)
CIK:        0001826892
Form:       8-K
Filed at:   2021-12-21T23:59:59+00:00
Accession:  0001193125-21-363150
Event type: leadership
Sentiment:  positive
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioAtla appoints Edward L. Williams to Board of Directors, increases board to 8
-------------------------------------------------------------------------------

- Board size increased from 7 to 8; Mr. Williams appointed as Class III director effective Dec 16, 2021.
- Mr. Williams will serve on the Audit Committee.
- Received initial grant of 25,000 stock options vesting over approximately 2 years under 2020 Equity Incentive Plan.
- Former SVP Biopharmaceuticals at Novo Nordisk (2006-2017) and VP at Novartis; currently special advisor to CEO of Ascendis Pharma.
- Standard indemnification agreement entered; no related-party transactions disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826892/000119312521363150/0001193125-21-363150-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826892/000119312521363150/d275731d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-363150

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer